Drugs / Ropeginterferon
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07249840 | Aug 2026 → Aug 2030 expected | — | Brigham and Women's Hospital | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07105319 | Nov 2021 → Jul 2025 | chronic myeloid leukemia | Dong-Wook Kim | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ropeginterferon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07105319 ↗ |
| Known as | ropeginterferon alfa-2b | “The goal of this clinical trial is to learn if the drug ropeginterferon alfa-2b can be used safely to treat patients with a JAK2 mutation and high risk features, but do not yet...” NCT07249840 ↗ |
| Modality | Protein / enzyme biologic | “long-acting next-generation mono-pegylated interferon alfa-2b” NCT07105319 ↗ |
| Route | Subcutaneous | “Ropeginterferon subcutaneously with 250 μg at week 0, 350 μg at week 2, 500 μg at week 4, and thereafter 500 μg bi-weekly until week 24.” NCT07105319 ↗ |